Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood
loss and allogeneic red blood cell transfusion in several clinical settings. With a growing …

Guidelines Management of severe peri-operative bleeding: Guidelines from the European
Society of Anaesthesiology and Intensive Care

Background Most treatments for postpartum haemorrhage (PPH) lack evidence of
effectiveness. New innovations are ubiquitous but have not been synthesized for ready …

Vasa previa carries a high risk of severe fetal morbidity and mortality due to fetal
hemorrhage caused by damage to unprotected fetal cord vessels upon membrane rupture …

OBJECTIVE Tranexamic acid is a cost-effective intervention for the prevention of postpartum
hemorrhage among women who undergo cesarean delivery, but the evidence to support its …

Background Postpartum haemorrhage (PPH) continues to stand as the primary cause of
maternal morbidity and mortality post-delivery, with twin pregnancies carrying a heightened …

Background In this meta-analysis, we aimed to update the clinical evidence regarding the
efficacy and safety of TXA in the prevention of PPH. Methods A literature search of PubMed …

Background Prophylactic use of tranexamic acid at the time of cesarean delivery has been
shown to decrease the calculated blood loss, but the effect on the need for blood …

Objective To evaluate the effectiveness of tranexamic acid (TXA) in reducing blood loss
during elective caesarean sections in women with and without risk factors for postpartum …

Background Tranexamic acid is a recommended treatment for women with a clinical
diagnosis of postpartum haemorrhage, but whether it can prevent bleeding is unclear. We …